about
Matriptase-3 is a novel phylogenetically preserved membrane-anchored serine protease with broad serpin reactivityMouse DESC1 is located within a cluster of seven DESC1-like genes and encodes a type II transmembrane serine protease that forms serpin inhibitory complexesRegulation of cell surface protease matriptase by HAI2 is essential for placental development, neural tube closure and embryonic survival in miceRXR alpha, a promiscuous partner of retinoic acid and thyroid hormone receptorsMatriptase initiates activation of epidermal pro-kallikrein and disease onset in a mouse model of Netherton syndromePlasminogen deficiency leads to impaired remodeling after a toxic injury to the liverRegulation of feto-maternal barrier by matriptase- and PAR-2-mediated signaling is required for placental morphogenesis and mouse embryonic survivalMembrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancerPlasminogen activators direct reorganization of the liver lobule after acute injuryReduced prostasin (CAP1/PRSS8) activity eliminates HAI-1 and HAI-2 deficiency-associated developmental defects by preventing matriptase activationTMPRSS13 deficiency impairs stratum corneum formation and epidermal barrier acquisitionRegulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independentGrowth and dissemination of Lewis lung carcinoma in plasminogen-deficient miceAccelerated wound healing by mTOR activation in genetically defined mouse models.Selective abrogation of the uPA-uPAR interaction in vivo reveals a novel role in suppression of fibrin-associated inflammationRole for the actomyosin complex in regulated exocytosis revealed by intravital microscopyM2-like macrophages are responsible for collagen degradation through a mannose receptor-mediated pathway.Type II transmembrane serine proteases.Mapping of two new human B-cell epitopes on HIV-1 gp120.Laser capture microdissection-based in vivo genomic profiling of wound keratinocytes identifies similarities and differences to squamous cell carcinomaDetection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography.Imaging specific cell surface protease activity in living cells using reengineered bacterial cytotoxinsQuantitative high-throughput screening identifies inhibitors of anthrax-induced cell deathThe plasminogen activation system enhances brain and heart invasion in murine relapsing fever borreliosis.Conditional deletion of neuronal cyclin-dependent kinase 5 in developing forebrain results in microglial activation and neurodegeneration.Rac1 is required for epithelial stem cell function during dermal and oral mucosal wound healing but not for tissue homeostasis in mice.Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma.The membrane-anchored serine protease prostasin (CAP1/PRSS8) supports epidermal development and postnatal homeostasis independent of its enzymatic activity.Membrane-anchored serine protease matriptase regulates epithelial barrier formation and permeability in the intestineMatriptase zymogen supports epithelial development, homeostasis and regenerationDeregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation.Efficient targeting of head and neck squamous cell carcinoma by systemic administration of a dual uPA and MMP-activated engineered anthrax toxin.Membrane-anchored serine proteases in vertebrate cell and developmental biologyExpression and genetic loss of function analysis of the HAT/DESC cluster proteases TMPRSS11A and HATComparative toxicity and efficacy of engineered anthrax lethal toxin variants with broad anti-tumor activitiesThe protease inhibitor HAI-2, but not HAI-1, regulates matriptase activation and shedding through prostasin.Potent antitumor activity of a urokinase-activated engineered anthrax toxin.Transport via the transcytotic pathway makes prostasin available as a substrate for matriptaseMT1-MMP controls tumor-induced angiogenesis through the release of semaphorin 4D.Peptide toxins directed at the matrix dissolution systems of cancer cells.
P50
Q24300747-3A0A7F31-ACE1-473B-B70B-352F443B3029Q24301907-2897A644-A8BB-4E07-92D0-90367378B286Q24313255-ACEDDB56-74BE-41C3-878E-48322E33BD67Q24555693-764C8DB0-7A42-4078-839A-E14127622894Q24609336-ABDD0358-9C19-480C-B63F-5C740A6D29A6Q24655869-B74D3031-108C-45EA-8D44-A9C325C66701Q27314964-664DDCFA-27B4-46DE-A5C7-15BB572FA48FQ28208507-E7AA7672-55DD-4BD8-BA99-0243511A2707Q28359705-4625009A-0E4B-488B-A026-344DBC4C4258Q28483094-094A0913-28B2-4FC6-B16D-9FE4C0516DF0Q28506622-E0592E06-285E-4ED0-8C84-2E5D713ACC72Q28584148-22B26A57-D689-498D-846A-DCC77DE53EB3Q28588467-278E5BA4-8E86-475E-9FA8-186157D5E562Q30389607-6C3D5365-C85E-4A40-A481-461B09435EE6Q30496585-BD33C074-5CD8-486B-9893-C99F5A2A206EQ30503563-0542E86B-D23E-4127-BEE4-803891755ECEQ30544968-3743882D-3855-4F28-821C-88049CDF7288Q30815077-FFED52BE-6585-4F66-AA13-A78B293722E8Q30955400-D182938D-84FA-4246-B150-7D45AD8189FAQ31147032-1A589455-DB63-4252-9D6D-C0A6FFB06850Q33208404-AF915147-E4EB-4BF6-9E11-5D3A0085D038Q33432028-835DCFDA-E7E7-4266-800A-910BC357F823Q33470990-4BCD394C-7C64-405C-A06D-F2FF1781B0B7Q33504867-83B622C1-0554-457B-8EB2-23F7B3C5CDE7Q33556356-B0B82F07-EC3B-4F28-A6EA-ADB60715D5C1Q33576782-7111AD6F-5507-4CBA-9846-B056AE5C6F8CQ33590611-1F5267CE-563B-466A-8860-4F6B847B9FB6Q33652121-AA9E3821-BDA3-439E-8C35-88DA7C4194BEQ33732689-72A1F5EC-5130-4A71-B7BD-AFF859BB574EQ33749952-242B5A50-2D9C-4A21-8B01-D57399D69CCCQ33917709-23492719-9A37-413D-88E6-9A6D41D4F1DFQ33927058-1D3CBB43-C356-4202-8C2D-351434F2D2E6Q33948580-1495F7B6-3D3F-41A2-AE8E-CF01E680A667Q33997003-09E12223-575B-42CE-919B-524BE1891B22Q34063766-B72833DD-C10B-4A72-ACC8-7208A9BF0814Q34070450-34D6A69D-A628-4086-B801-9EC11D9DB976Q34470439-44DE6DB2-A2E0-4D89-89BB-8D2AC7A3CDB4Q34568634-3BE63B4D-7808-4B88-B201-E08FAD66AFCDQ34598008-FC4FE2CE-0131-4E39-B983-91AF2F1AEBC0Q34762045-3B37A21A-F512-4E34-BEA2-2664A37E4437
P50
description
chercheur
@fr
onderzoeker
@nl
senior investigator at the U.S. National Institutes of Health
@en
name
Thomas H Bugge
@ast
Thomas H Bugge
@es
Thomas H Bugge
@nl
Thomas H Bugge
@sl
Thomas H. Bugge
@de
Thomas H. Bugge
@en
Thomas H. Bugge
@fr
type
label
Thomas H Bugge
@ast
Thomas H Bugge
@es
Thomas H Bugge
@nl
Thomas H Bugge
@sl
Thomas H. Bugge
@de
Thomas H. Bugge
@en
Thomas H. Bugge
@fr
altLabel
T Bugge
@en
T H Bugge
@en
T. Bugge
@en
T. H. Bugge
@en
Thomas Bugge
@en
Thomas H Bugge
@en
Thomas Henrik Bugge
@en
prefLabel
Thomas H Bugge
@ast
Thomas H Bugge
@es
Thomas H Bugge
@nl
Thomas H Bugge
@sl
Thomas H. Bugge
@de
Thomas H. Bugge
@en
Thomas H. Bugge
@fr
P106
P108
P937
P973
P1006
P214
P244
P269
P6366
P1006
P108
P1153
7005035630